

Index

Note: Page numbers set **bold** or *italic* indicate headings or figures, respectively.

A

- Abscess 70
 - granulomatous 71
- Acetazolamide 58
- Acute filler-related infection, antibiotic treatment regimens for 98
- Age-related sagging 7
- Alcohol consumption 41, 108
- Alcohol-based solutions 15
- Allergen 37
- American Society for Aesthetic Plastic Surgery 4
- American Society for Dermatologic Surgery 4
- Amoxicillin 72
- Amphadase 109
- Anastomosing arterial supply 112
- Angioedema 35, 37
- Antibiotics 72, 98, 98
- Antibody-mediated edema 38
- Anticoagulants 36
- Antihistamines 37
- Antithrombotic effect 41
- Apraclonidine 58
- Arnica montana 37
- ArteColl microspheres 87
- ArteFill 87
- ArtePlast 87
- Aseptic technique 15, 72, 100
- Aspirin 14, 26, 40, 57, 111

B

- Bacterial biofilms 96–97
- BellaFill 87, 89, 104, 117
- Belotero Balance 104
- Benzocaine 49
- Benzocaine–lidocaine–tetracaine ointment 49
- Biodegradable fillers 67
- Biofilms 70, 70, 72
 - formation 80
 - infections and 118
 - related nodules 92
 - treatment 99
- Blindness 53–55, 111
- Bromelain 41
- Brow, glabella and 112
- Bruising 37, 107
 - swelling and 35
 - algorithm of treatment 38
 - case report 42
 - causes 36
 - clinical presentation 35
 - management 36

- techniques for prevention 39

C

- CaHA, *see* Calcium hydroxylapatite (CaHA)
- Calcium hydroxylapatite (CaHA) 3, 16, 24, 56, 67, 81, 88–91, 95, 104, 116, 117
- Candida albicans 15
- Cannula 47, 50
- Cannulation 105
- CBCT, *see* Cone beam CT (CBCT)
- Cellulitis 28
- CHA fillers 25
- Cheek fat compartments 19
- Chin augmentation 12, 62
- Chlorhexidine 118
- Chlorhexidine gluconate 15
- Chloroxylenol 118
- Ciprofloxacin 72
- Clarithromycin 72
- Cobblestoning 28
- Cohesivity 105
- Collagen 95
- Compartments, facial fat 19
 - cheek fat compartments 19
 - forehead and temporal fat compartment 20
 - jowl fat compartment 20
 - nasolabial fat compartment 19
 - orbital fat compartment 20
- Computed tomography (CT) 19, 22, 22, 78
- Cone beam CT (CBCT) 22
- Consent 13
- Contour deformities 15
- Cosmetic procedures 3
 - by race/ethnicity 4
 - nonsurgical procedure 3
 - patients and practitioners, epidemiology of 4
- Counseling and setting expectations 14
- COX-2, inhibition of 41
- CT, *see* Computed tomography (CT)
- Cutaneous ischemic 56
- Cystic granulomas 89

D

- Danger zones of the face 112
- Delayed-onset complications 107

- Delayed-onset nodules 116
 - BellaFill/polydimethylsiloxane–bovine collagen 117
 - Radiesse/calcium hydroxylapatite 117
 - Sculptra Aesthetic/poly-L-lactic acid 116
- Dermal fillers 3–6, 22, 69, 74, 83
 - algorithm for treatment of vascular compromise due to 59
 - classification of 67
- Dermal fillers, hypersensitivity reactions to 67
 - cases 72
 - clinical presentation 68
 - biofilms 70
 - granulomatous reactions 70
 - type IV hypersensitivity reactions 69
 - dermal filler hypersensitivity reaction management algorithm 71
 - biofilms 72
 - type I hypersensitivity 71
 - type IV hypersensitivity 71
 - prednisone versus methylprednisolone 74
 - prevention, techniques for 72
- Diagnostic and Statistical Manual of Mental Disorders-IV-TR (DSM-IV-TR) 46
- Doppler function 29
- DSM-IV-TR, *see* Diagnostic and Statistical Manual of Mental Disorders-IV-TR (DSM-IV-TR)

E

- Early-onset nodules 88
- Ecchymosis 35–36, 50
- Edema
 - algorithm for the management of 38
 - antibody-mediated (Type I hypersensitivity) 38
 - T lymphocyte-mediated (Type IV hypersensitivity) 39
 - management of 40
- Erythrocytes 35

- Escherichia coli 15, 96
- Excisional biopsy 81

F

- Facial fat compartments, imaging anatomy of 19
 - cheek fat compartments 19
 - forehead and temporal fat compartment 20
 - jowl fat compartment 20
 - nasolabial fat compartment 19
 - orbital fat compartment 20
- FBG, *see* Foreign body granuloma (FBG)
- FDA, *see* Food and Drug Administration (FDA)
- 18-FDG, *see* 18-Fluorodeoxyglucose (18-FDG)
- Filler complications 26
 - long-term complications 27
 - filler migration 28
 - foreign body granuloma (FBG) 27
 - infection 28
 - noninflammatory nodule 27
 - scarring 28
 - short-term complications 26
- Filler crash kit 110
- Filler embolization 112
- Filler embolus 55–56
- Filler imaging 22
- Filler material, sonographic evaluation of 22
- Filler migration 28, 78–79, 81–82
- Filler preparation 100
- Filler rescue kit 110
- Filler type, normal imaging features by 23
 - long-lasting (slowly resorbed) fillers 24
 - permanent fillers 25
 - temporary (rapidly resorbed) fillers 23
- Filler-induced pain 51
- Fillers 103
- FISH tests, *see* Fluorescence in-situ hybridization (FISH) tests
- Fitzpatrick skin types 4
- Fluorescence in-situ hybridization (FISH) tests 71, 96

18-Fluorodeoxyglucose (18-FDG) 23
 5-Fluorouracil (5-FU) 71–72, 92
 Food and Drug Administration (FDA) 16, 27, 41, 70, 81, 87, 103
 – FDA-approved fillers available in the United States 104
 Forehead and temporal fat compartment 20
 Foreign body granuloma (FBG) 27
 – grades of 89
 Frequency 21
 5-FU, *see* 5-Fluorouracil (5-FU)

G

Galea 79
 Garlic 41
 Gate Control Theory of Pain 49
 Ginkgo 41
 Ginseng 41
 Glabella 8
 – and brow 112
 Glycocalyx 70
 Granuloma, *see* Nodules and granulomas
 – cystic 89
 – defined 89
 – sclerosing 89
 Granulomatous abscesses 71
 Granulomatous reactions 70
 Gravity 79

H

HA fillers, *see* Hyaluronic acid (HA) fillers
 Hematoma 29, 35–36
 Hemostasis 68
 Herpes reactivation and pain 50
 Herpes simplex virus (HSV) 50, 97, 97
 Herpes virus reactivation 13
 Hexachlorophene 118
 HFUS, *see* High-frequency ultrasound (HFUS)
 High-frequency ultrasound (HFUS) 21, 21, 22–23, 27
 HIV, *see* Human immunodeficiency virus (HIV)
 HSV, *see* Herpes simplex virus (HSV)
 Human immunodeficiency virus (HIV) 16

Hyaluronic acid (HA) fillers 3, 14–15, 22, 28, 37, 42, 47, 50, 56, 62, 67–68, 78, 81, 88–89, 91, 95, 97, 104, 107, 113
 Hyaluronidase 55–56, 61, 62, 72, 109, 112
 Hydase 109
 Hydrogel polymers 95
 Hylenex 57
 Hyperbaric oxygen therapy 57
 Hyperpigmentation 4
 Hypersensitivity 67
 – type I 71
 – type IV 71
 Hypersensitivity reactions to dermal fillers 67
 – cases 72
 – classification of dermal fillers 67
 – clinical presentation 68
 – biofilms 70
 – granulomatous reactions 70
 – type IV hypersensitivity reactions 69
 – dermal filler hypersensitivity reaction management algorithm 71
 – biofilms 72
 – type I hypersensitivity 71
 – type IV hypersensitivity 71
 – prednisone versus methylprednisolone 74
 – prevention, techniques for 72
 Hypertrophic scars 28
 Hypochlorous acid 15, 118
 Hypopigmentation 4

I

Imaging complications, techniques for 19
 – facial fat compartments, imaging anatomy of 19
 – cheek fat compartments 19
 – forehead and temporal fat compartment 20
 – jowl fat compartment 20
 – nasolabial fat compartment 19
 – orbital fat compartment 20
 – filler complications 26
 – long-term complications 27
 – short-term complications 26
 – filler type, normal imaging features by 23
 – long-lasting (slowly resorbed) fillers 24
 – permanent fillers 25
 – temporary (rapidly resorbed) fillers 23
 – techniques for prevention through imaging 29
 Imaging modalities 20
 – computed tomography (CT) 22
 – high-frequency ultrasound (HFUS) 21
 – magnetic resonance imaging (MRI) 20
 – positron emission tomography-computed tomography (PET-CT) 23
 Infection 28, 95
 – algorithm of treatment 99
 – case report 101
 – causes 96
 – herpes 97
 – clinical presentation 95
 – acute infection 95
 – chronic infection 96
 – management 98
 – abscess 99
 – antibiotic choice 98
 – biofilm-related nodule treatment 99
 – prognosis 98
 – techniques for prevention 99
 – filler preparation 100
 – future innovations 101
 – patient history 99
 – photographs 100
 – previous filler injections 100
 – procedure planning 100
 – setup and injection technique 101
 – skin disease 100
 – skin preparation 100
 – systemic disease/recent procedures 100
 Infections and biofilms 118
 Inflammatory cytokines 37
 Inflammatory early and late nodules 91
 Infraorbital artery 113
 Infraorbital nerve block 50
 Injectable implants, *see* Dermal fillers
 Injection technique 79, 105
 Intense pulsed light (IPL) 38
 Intra-arterial injection, complications of 29
 Intralesional corticosteroid injections 71
 Intraoperative pain-related complications 50
 Intravascular injection 80
 IPL, *see* Intense pulsed light (IPL)
 Isopropyl alcohol 118

J

Jowl fat compartment 20
 Juvederm Ultra Plus XC 104
 Juvederm Ultra XC 104
 Juvederm Volbella XC 104

K

KTP laser, *see* Potassium titanyl phosphate (KTP) laser

L

Labiomandibular fold 101
 Late-onset nodules 89
 LED, *see* Light emitting diode (LED)
 – causes 96
 Lidocaine 49, 111
 Light emitting diode (LED) 14
 Light-based vein mapping 29
 Lighting 14
 Lips 115
 Liquid silicone 25–26
 Livedo reticularis 54, 54
 Long-lasting (slowly resorbed) fillers 24
 Long-pulsed light 108
 Lower face 12
 Lymphatic spread 79

M

Macrophages 35, 89
 Magnetic resonance imaging (MRI) 19, 20, 21, 78
 Massage 79
 Massager 49
 2-Methyl-3-phytyl-1,4-naphthoquinone 38
 Methylene blue 19
 Methylprednisolone 74
 – prednisone versus 74
 Midface 11
 Migration 77
 – algorithm of treatment 81
 – case report 83
 – causes 79
 – biofilm formation 80
 – gravity 79
 – injection technique 79
 – intravascular injection 80
 – lymphatic spread 79
 – massage 79
 – muscle activity 79
 – pressure-induced displacement 80
 – clinical presentation 78
 – management 81
 – techniques for prevention 81
 Mineral oil (Vaseline) 77
 Mohs defect 60

- MRI, *see* Magnetic resonance imaging (MRI)
- Muscle activity 79
- Muscle movement 8
- Mycobacteria 96, 98
- ## N
- Nasolabial fat compartment 19
- Nasolabial fold (NLF) 12, 101, 114
- Nd:YAG laser, *see* Neodymium-doped yttrium aluminum garnet (Nd:YAG) laser
- Near-infrared (NIR) light 29
- Needle prick and needle phobia, pain related to 46
- Needle-related fear and pain, techniques to reduce 47
- Neodymium-doped yttrium aluminum garnet (Nd:YAG) laser 38, 108
- Nerve blocking agents 47
- Nerve blocks 50
- Neuromodulators 4
- Neutrophils 35
- NIR light, *see* Near-infrared (NIR) light
- Nitroglycerin 57
- Nitroglycerine 111
- NLF, *see* Nasolabial fold (NLF)
- Nodule formation and algorithmic approach 93
- Nodules and granulomas 87
- algorithmic approach to nodules 93
 - case example 92
 - early-onset nodules 88
 - historical perspective 87
 - late-onset nodules 89
 - granuloma defined 89
 - management 90
 - biofilm-related nodules 92
 - collection/misplacement 91
 - inflammatory early and late nodules 91
 - noninfectious late inflammatory nodules 91
 - noninflammatory early nodules 91
- Non-antibody-mediated edema 35
- Non-HA fillers 91
- Nonhyaluronic acid fillers 111
- Noninfectious late inflammatory nodules 91
- Noninflammatory early nodules 91
- Noninflammatory nodule 27
- Nonpainful sensory stimulation 48
- Nonsteroidal anti-inflammatory drugs (NSAIDs) 26, 36, 40, 72
- Nose 112
- NSAIDs, *see* Nonsteroidal anti-inflammatory drugs (NSAIDs)
- ## O
- Ocular massage 112
- Orbicular retaining ligament (ORL) 19–20
- Orbital fat compartment 20
- ORL, *see* Orbicular retaining ligament (ORL)
- Oxy-hemoglobin 38
- ## P
- PAAG, *see* Polyacrylamide hydrogels (PAAG)
- Pain/tenderness 46–47
- intraoperative pain-related complications 50
 - needle-related fear and pain, techniques to reduce 47
 - nerve blocking agents 47
 - postoperative pain 50
 - recognition 47
 - related to needle prick and needle phobia 46
 - relaxation 47
 - topical anesthetics 49
 - vibration 48–49
- Paraffin 77
- PCR, *see* Polymerase chain reaction (PCR)
- Perception drift 13
- Permanent fillers 25, 67
- PET-CT, *see* Positron emission tomography-computed tomography (PET-CT)
- Photographs 100
- Photography 13
- appearance 13
 - background 13
 - consent 13
 - lighting 14
 - positioning 14
- Plastic Surgery Statistics Report (2020) 4
- PLLA, *see* Poly-L-lactic acid (PLLA)
- PMMA, *see* Polymethylmethacrylate (PMMA)
- Poly L-lactic acid (PLLA) 89
- Poly-L-lactic acid (PLLA) 104
- Poly-L-lactic acid (PLLA) 3, 5, 16, 24, 27–28, 67, 88, 90, 95, 97, 116
- Polyacrylamide 27–28, 97
- Polyacrylamide hydrogels (PAAG) 25
- Polyalkylimide 25
- Polymerase chain reaction (PCR) 96
- Polymethylmethacrylate (PMMA) 16, 24–25, 27, 71, 81, 87–91, 95, 104, 116
- Polymethylmethacrylate-bovine collagen 117
- Polytetrafluoroethylene 26
- Polytetrafluoroethylene 25
- Positioning 14
- Positron emission tomography-computed tomography (PET-CT) 23
- Potassium titanyl phosphate (KTP) laser 38
- Povidone-iodine 15
- Pre-injection planning 7
- anatomical considerations 7
 - lower face 12
 - midface 11
 - upper face 8
 - aseptic technique 15
 - counseling and setting expectations 14
 - photography 13
 - appearance 13
 - background 13
 - consent 13
 - lighting 14
 - positioning 14
 - preprocedure evaluation 13
 - product selection/appropriate use of filler 15
- Prednisone 74
- Prednisone versus methylprednisolone 74
- Pressure-induced displacement 80
- Prilocaine 49
- Propionibacterium acnes 97
- Prothrombin time (PT) 13
- Pseudo-abscesses, *see* Granulomatous abscesses
- Pseudomonas 97
- Pseudomonas aeruginosa 15
- PT, *see* Prothrombin time (PT)
- Pulsed dye laser 108
- Purpura 54, 54
- ## R
- Racial variations in aging face 7, 9
- Radiesse 104
- Radiesse/calcium hydroxylapatite 117
- Radiofrequency (RF) pulses 20
- Rayleigh scattering, *see* Tyndall effect
- Recognition 47
- Relaxation 47
- Resorbable fillers 95
- Restylane 68
- Restylane Defyne 104
- Restylane L 104
- Restylane Lyft 104
- Restylane Refyne 104
- Restylane Silk 104
- Retro-orbicularis fascia 79
- Revanesse Versa 104
- RF pulses, *see* Radiofrequency (RF) pulses
- RHA 2 104
- RHA 3 104
- RHA 4 104
- RHA Redensity 104
- Rheology 103
- ## S
- S. epidermidis 71, 96–97
- Saline injections 56
- Scarring 28
- Sclerosing granulomas 89
- Sculptra Aesthetic 104, 116
- Semi-permanent fillers 67
- Serotonin 37
- Silicone 16, 27, 71, 95
- “Silicone-only” sequence 20–21
- Skin blanching 53, 53
- Skin necrosis 110
- Skin preparation 100
- Small-gauge cannulas 61
- SMAS, *see* Superficial musculoaponeurotic system (SMAS)
- Soft tissue augmentation 103
- Soft tissue fillers, inappropriate placement of 108
- *See also* Dermal fillers
 - Tyndall effect 108
- Soft tissue necrosis 53
- Soft tissue rejuvenation 77
- Staphylococcus aureus 15, 96
- Pseudomonas 97
- Sterile technique 118
- Steroids 37, 71–72
- Streptococcus pyogenes 96
- Superficial musculoaponeurotic system (SMAS) 19, 79, 80
- Superficial temporal artery 10
- Swelling and bruising 35
- algorithm of treatment 38
 - case report 42
 - causes 36
 - clinical presentation 35
 - management 36
 - techniques for prevention 39

T

- T lymphocyte-mediated (Type IV hypersensitivity) 39
- T-lymphocytes 70
- Technique-related
 - complications 103, 107
 - bruising 107
 - delayed nodules 116
 - Bellafill/
 - polymethylmethacrylate-bovine collagen 117
 - Radiesse/calcium hydroxylapatite 117
 - Sculptra Aesthetic/poly-L-lactic acid 116
 - fillers 103
 - inappropriate placement of soft tissue fillers 108
 - Tyndall effect 108
 - infections and biofilms 118
 - injection techniques 105
 - vascular compromise 110
 - blindness 111
 - danger zones of the face 112

- glabella and brow 112
- infraorbital 113
- lips 115
- nasolabial fold 114
- nose 112
- skin necrosis 110
- Temporary (rapidly resorbed) fillers 23
- Temporary and semi-permanent fillers 67
- Tetracaine 49
- Topical anesthetics 49
- Transillumination 42
- Triamcinolone 71
- Trichophyton
 - mentagrophytes 15
- Tyndall effect 11, 108
- Type I hypersensitivity 71
- Type IV hypersensitivity 69, 71

U

- Ultrasound (US) 21, 29, 78
- Upper face 8

US, *see* Ultrasound (US)

V

- VAD, *see* Vibration Anesthesia Device (VAD)
- Vascular complications 55
- Vascular compromise 53, 55, 110
 - algorithm of treatment 58
 - blindness 111
 - case report 61
 - causes 55
 - clinical presentation 53
 - danger zones of the face 112
 - glabella and brow 112
 - infraorbital 113
 - lips 115
 - management 55
 - nasolabial fold 114
 - nose 112
 - skin necrosis 110

- techniques for prevention 60
- Vascular occlusion 54–55, 60
- Vibration 48–49
- Vibration Anesthesia Device (VAD) 48
- Violaceous reticulated erythema 54
- Viral prophylaxis 13
- Viscoelasticity 105
- Vitamin K 38
- Vitrase 109
- Vycross technology 70

W

- Water 20

Z

- Zyderm I 15
- Zyderm II 15
- Zyplast 15